-
Express Pfizer’s JAK inhibitor gains its fifth indication for the treatment of active ankylosing spondylitis
Time of Update: 2022-01-03
▎The content team editor of WuXi AppTec On December 14, 2021, Pfizer announced that the US FDA has approved the supplementary new drug application (sNDA) for the oral small molecule JAK inhibitor tofacitinib (tofacitinib, English trade name Xeljanz) It is used to treat adult patients with active ankylosing spondylitis (AS) who have insufficient response or intolerance to one or more tumor necrosis factor (TNF) blockers .
-
Why are patients with lupus prone to osteoporosis?
Time of Update: 2021-12-31
Sex hormones have a protective effect on bone metabolism, and postmenopausal SLE patients have an increased risk of osteoporosis and related fractures .
-
New Phytologist Hong Kong Baptist University’s Xia Yilu team reveals the important functions of E3 ubiquitin ligases PUB2 and PUB4 in the Arabidopsis PTI immune response
Time of Update: 2021-12-30
The study found that the E3 ubiquitin ligase family proteins PUB2 and PUB4 play a key role in PTI signal transduction through their ARM repeat sequences .
-
The dual role of Nature MORC3 in antiviral immunity
Time of Update: 2021-12-30
Vance research group from the University of California at Berkeley published an article entitled Self-guarding of MORC3 enables virulence factor-triggered immunity in Nature, focusing on how the body fights virus invasion .
-
The latest "Nature": Chinese scientists reveal the pathogenesis of vitiligo
Time of Update: 2021-12-30
▲In fibroblasts, interferon gamma signal affects the content of killer CD8+ T cells (picture source: Chen Ting's research group) Researcher Chen Ting said that this study not only reveals the pathogenesis of vitiligo, but also for subsequent drugs and Clinical research also has a driving effect: "The model we have established is of great help to drug design and testing, and is expected to promote disease treatment in the future .
-
Sci Adv Zhou Qing/Yu Xiaomin's team reveals a new mechanism by which OTULIN deficiency leads to autoinflammatory diseases
Time of Update: 2021-12-30
The NEMO and RIPK1 in peripheral blood mononuclear cells (PBMCs) of patients with OTULIN deficiency have excessive linear ubiquitin chain accumulation, which activates the NF-κB signaling pathway and leads to the release of pro-inflammatory cytokines (PNAS, 2016) .
-
Nature Chi Hongbo's team builds T cell nutrition-immune regulatory network
Time of Update: 2021-12-30
Through CRISPR screening, the authors constructed the mTORC1 regulatory network in T cells, elucidating the connection between nutritional signals and immune signals .
The authors found that CCDC101 can inhibit the expression of nutrient transporters such as GLUT1 and downstream signals of GATOR2-RAGA, thereby limiting mTORC1 activation to maintain T cell function homeostasis and lineage stability .
-
The latest consensus!
Time of Update: 2021-12-29
According to different autoimmune attack targets, immune response types and clinical manifestations, it is mainly divided into the following categories: Autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and overlapping syndromes where the main features of any of the above two diseases appear at the same time .
-
Air Force Military Medical University Jin Yan/Li Bei Research Group Advanced Science: "Mitochondrial Repair Device" Remodels Mesenchymal Stem Cell Mitochondrial Function to Treat Inflammatory Bone Disease
Time of Update: 2021-12-29
Innovation: The research group of Professor Jin Yan/Li Bei of the Third Affiliated Hospital of Air Force Military Medical University and the research group of Professor Chen Xin of Xi’an Jiaotong University have discovered a new mechanism of mitochondrial dysfunction in mesenchymal stem cells (MSCs) in the inflammatory microenvironment.
-
Courier benefits a wide range of severe asthma patients, "first-in-class" antibody therapy is approved by the FDA
Time of Update: 2021-12-29
The US FDA granted tezepelumab breakthrough therapy designation in September 2018 for the treatment of patients with severe asthma without eosinophilic phenotype .
-
Express the first paragraph!
Time of Update: 2021-12-28
▎ WuXi AppTec content team editor December 20, 2021, Amgen announced that the US FDA has expanded the indications of Otezla (apremilast) to treat plaque psoriasis suitable for phototherapy or systemic therapy Sick adult patients .
-
Immunity inducible costimulatory molecule ICOS in the differentiation of CD8+ T lymphocytes
Time of Update: 2021-12-28
The research article of T cells revealed that in the mouse acute infection model, the inducible costimulatory molecule ICOS can specifically mediate the efficient maturation and differentiation of CD8+ tissue-resident memory T cells in non-lymphoid tissues .
-
Courier Lilly's Phase 3 Eczema Therapy Trial reports another good news, and plans to submit a regulatory application next year
Time of Update: 2021-12-28
▎Editor of WuXi AppTec's content team On December 21, 2021, Eli Lilly and Company announced that the IL-13 inhibitor lebrikizumab and topical corticosteroid (TCS) are under investigation for the treatment of patients with moderate to severe atopic dermatitis.
-
Research reveals a new mechanism for deubiquitinating enzyme OTUD1 to inhibit enteritis
Time of Update: 2021-12-28
The study revealed that the deubiquitinating enzyme OTUD1 inhibits the production of pro-inflammatory cytokines mediated by the NF-κB pathway in intestinal immune cells by removing the K63 polyubiquitin chain of RIPK1, thereby inhibiting the molecular mechanism of enteritis.
-
Novartis' ligelizumab fails to beat Xolair in spontaneous urticaria study
Time of Update: 2021-12-27
Blood vesselNovartis announced on Monday that in the Phase III PEARL 1 and 2 studies of patients with chronic spontaneous urticaria, the experimental drug ligelizumab failed to show an advantage over Xolair (omalizumab) .
-
Br J Dermatol: Efficacy and safety of ixekizumab and guselkumab in the treatment of moderate to severe plaque psoriasis
Time of Update: 2021-12-27
Recently, a randomized trial published in Br J Dermatol compared the skin and nail clearance rates after treatment with ixekizumab and guselkumab, as well as patient-reported results .
guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial .
-
JAMA: Active therapeutic drug monitoring (TDM) can improve the rate of disease control during maintenance treatment with infliximab and reduce the risk of deterioration
Time of Update: 2021-12-27
For patients with chronic immune-related inflammatory diseases receiving infliximab maintenance treatment, active therapeutic drug monitoring (TDM) can effectively control the disease and reduce the risk of treatment failure.
-
ARD: Survival rates of French hospitalized patients with systemic lupus erythematosus after COVID-19-related organ failure: a national study
Time of Update: 2021-12-27
The study analyzed the incidence, specific results and related factors of COVID-19- related organ failure (AOF) in French patients with systemic lupus erythematosus (SLE) .
The study analyzed the incidence, specific results and related factors of COVID-19- related organ failure (AOF) in French patients with systemic lupus erythematosus (SLE) .
-
Eli Lilly's lebrikizumab meets the primary endpoint of the atopic dermatitis study
Time of Update: 2021-12-27
Quality of life childrenEli Lilly said on Tuesday that the third phase III study of lebrikizumab in patients with moderate to severe atopic dermatitis (AD) met all its primary and key secondary endpoints .
-
ARD: The short-term dose and duration-dependent risk of cardiovascular events of glucocorticoids in patients with rheumatoid arthritis initially treated with glucocorticoids
Time of Update: 2021-12-27
The study identified in the original unused glucocorticoids RA after the start of the use of corticosteroids in patients, whether in a dose-dependent manner and duration of the increase in the short term cardiovascular events (CVE) risk .
